Quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: the global DISCOVER study

被引：0
|
作者：
Nicolucci, A. [1 ]
Gomes, M. B. [2 ]
Khunti, K. [3 ]
Kosiborod, M. [4 ]
Pocock, S. [5 ]
Rathmann, W. [6 ]
Shestakova, M. V. [7 ]
Shimomura, I. [8 ]
Watada, H. [9 ]
Chen, H. [10 ]
Cid-Ruzafa, J. [11 ]
Fenici, P. [12 ]
Hammar, N. [13 ]
Tang, F. [4 ]
Ji, L. [14 ]
机构：
[1] Ctr Outcomes Res & Clin Epidemiol, Pescara, Italy
[2] Univ Estado Rio De Janeiro, Rio De Janeiro, Brazil
[3] Univ Leicester, Leicester, Leics, England
[4] St Lukes Mid Amer Heart Inst, Kansas City, MO USA
[5] London Sch Hyg & Trop Med, London, England
[6] German Diabet Ctr, Dusseldorf, Germany
[7] Diabet Inst, Endocrinol Res Ctr, Moscow, Russia
[8] Osaka Univ, Osaka, Japan
[9] Juntendo Univ, Tokyo, Japan
[10] AstraZeneca, Gaithersburg, MD USA
[11] Evidera, Barcelona, Spain
[12] AstraZeneca, Cambridge, England
[13] AstraZeneca Gothenburg, Molndal, Sweden
[14] Peking Univ, Peoples Hosp, Beijing, Peoples R China
来源：
DIABETOLOGIA | 2018年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
344
引用
收藏
页码：S173 / S174
页数：2
相关论文
共 50 条
  • [21] Newer second-line glucose-lowering drugs versus thiazolidinediones and cirrhosis risk in type 2 diabetes
    Yang, Jeff Y.
    Alexopoulos, Anastasia
    Moon, Andrew M.
    Kim, Hannah
    Pate, Virginia
    Barritt, A. Sidney
    Sturmer, Til
    Buse, John B.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 606 - 606
  • [22] Treatment patterns and associated factors in 13,379 patients with type 2 diabetes initiating a second-line therapy: the DISCOVER study
    Nicolucci, A.
    Arya, N.
    Charbonnel, B.
    Cid-Ruzafa, J.
    Fenici, P.
    Gomes, M. B.
    Hammar, N.
    Khunti, K.
    Kosiborod, M.
    Shestakova, M. V.
    Watada, H.
    Shimomura, I.
    Tang, F.
    Pocock, S.
    DIABETOLOGIA, 2017, 60 : S301 - S302
  • [23] Glycaemic control in 14,005 patients with type 2 diabetes initiating second-line therapy in 36 countries: the DISCOVER study
    Ji, L.
    Nicolucci, A.
    Arya, N.
    Cid-Ruzafa, J.
    Fenici, P.
    Gomes, M. B.
    Hammar, N.
    Kosiborod, M.
    Pocock, S.
    Shestakova, M. V.
    Watada, H.
    Shimomura, I.
    Tang, F.
    Khunti, K.
    DIABETOLOGIA, 2017, 60 : S140 - S141
  • [24] Glycaemic Control in 14,005 Patients with Type 2 Diabetes Initiating Second-Line Therapy in 36 Countries: The DISCOVER Study
    Khunti, Kamlesh
    Arya, Nikita
    Cid-Ruzafa, Javier
    Fenici, Peter
    Gomes, Marilia B.
    Hammar, Niklas
    Ji, Linong
    Kamal, Samer
    Kosiborod, Mikhail
    Pocock, Stuart
    Shestakova, Marina V.
    Shimomura, Iichiro
    Tang, Fengming
    Watada, Hirotaka
    Nicolucci, Antonio
    DIABETES, 2017, 66 : A447 - A447
  • [25] Treatment Patterns and Associated Factors in 13,379 Patients with Type 2 Diabetes Initiating a Second-Line Therapy: The DISCOVER Study
    Nicolucci, Antonio
    Arya, Nikita
    Charbonnel, Bernard
    Cidruzafa, Javier
    Fenici, Peter
    Gomes, Marilia B.
    Hammar, Niklas
    Kamal, Samer
    Khunti, Kamlesh
    Kosiborod, Mikhail
    Shestakova, Marina V.
    Shimomura, Iichiro
    Tang, Fengming
    Watada, Hirotaka
    Pocock, Stuart
    DIABETES, 2017, 66 : A326 - A326
  • [26] Individualized HbA1c Targets in People with Type 2 Diabetes Initiating Second-Line Therapy-The Global DISCOVER Study
    Khunti, Kamlesh
    Chen, Hungta
    Cid-Ruzafa, Javier
    Fenici, Peter
    Gomes, Marilia B.
    Hammar, Niklas
    Kennedy, Kevin
    Kosiborod, Mikhail
    Pocock, Stuart
    Shestakova, Marina V.
    Shimomura, Iichiro
    Surmont, Filip
    Ji, Linong
    DIABETES, 2018, 67
  • [27] Associations between second-line glucose-lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose-lowering treatment intensification: The DISCOVER study
    Khunti, Kamlesh
    Charbonnel, Bernard
    Cooper, Andrew
    Gomes, Marilia B.
    Ji, Linong
    Leigh, Paul
    Nicolucci, Antonio
    Rathmann, Wolfgang
    Shestakova, Marina V.
    Siddiqui, Afrah
    Tang, Fengming
    Watada, Hirotaka
    Chen, Hungta
    DIABETES OBESITY & METABOLISM, 2021, 23 (08): : 1823 - 1833
  • [28] Risk of cardiovascular events in type 2 diabetes patients initiating second-line therapy with glucose lowering drugs: A population-based analysis
    Moura, Cristiano S.
    Elharram, Malik
    Abrahamowicz, Michal
    Bernatsky, Sasha
    Behlouli, Hassan
    Raparelli, Valeria
    Pilote, Louise
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 484 - 484
  • [29] Early versus late intensification of glucose-lowering therapy in patients with type 2 diabetes: Results from the DISCOVER study
    Ji, Linong
    Bonnet, Fabrice
    Chen, Hungta
    Cooper, Andrew
    Hammar, Niklas
    Leigh, Paul
    Saraiva, Gabriela Luporini
    Ramirez, Larisa
    Medina, Jesus
    Nicolucci, Antonio
    Rathmann, Wolfgang
    Shestakova, Marina, V
    Surmont, Filip
    Tang, Fengming
    Watada, Hirotaka
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 178
  • [30] Vascular events in patients with type 2 diabetes in the year following initiation of second-line therapy: the DISCOVER study
    Surmont, F.
    Chen, H.
    Cid-Ruzafa, J.
    Fenici, P.
    Gomes, M. B.
    Khunti, K.
    Pocock, S.
    Rathmann, W.
    Shestakova, M. V.
    Shimomura, I.
    Tang, F.
    Watada, H.
    Ji, L.
    Hammar, N.
    Kosiborod, M.
    DIABETOLOGIA, 2018, 61 : S562 - S562
12345